Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment (Current Medical Research Opinion (2008) 24, 3, (625-637)) DOI:10.1185/030079908X273264;Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment

Current Medical Research and Opinion

Volumn 24, Issue 3, 2008, Pages 625-637

  Wizemann, Volker ^a   Rutkowski, Boleslaw ^b   Baldamus, Conrad ^c   Scigalla, Paul ^d   Koytchev, Rossen ^e  

^a Patienten Heimversorgung   (Germany)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c UNIVERSITY OF COLOGNE   (Germany)

^d International Clinical Research Consulting   (Germany)

^e CCDRD AG   (Germany)

Author keywords

Biosimilar; Efficacy; Epoetin zeta; Erythropoietin; Maintenance treatment; Safety; Therapeutic equivalence

Indexed keywords

EPOETIN ZETA; ERYTHROPOIETIN; ERYTHROPOIETIN ANTIBODY; HEMOGLOBIN; NEUTRALIZING ANTIBODY; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; INFESTATION; KIDNEY ANEMIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PARESTHESIA; PHASE 3 CLINICAL TRIAL; POLYNEUROPATHY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; SKIN DISEASE; THORAX DISEASE; TREATMENT DURATION; VASCULAR DISEASE;

EID: 41149131276     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X292010     Document Type: Erratum

References (46)

1. Barbone FP, Johnson DL, Farrell FX, et al. New epoetin molecules and novel therapeutic approaches. Nephrol Dial Transplant 1999;14(Suppl 2):80-4
2. Downey P. Recombinant human erythropoietin as a treatment for anemia of prematurity. J Perinat Neonatal Nurs 1997;11:57-68
3. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004;43:649-59
4. Levin A. Identification of patients and risk factors in chronic kidney disease - evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant 2001;16(Suppl 7):57-60
5. Monnerat C, Leyvraz S. Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia [in German]. Schweiz Rundsch Med Prax 1999;88:178-88
6. Levin A. How should anaemia be managed in pre-dialysis patients? Nephrol Dial Transplant 1999;14(Suppl 2):66-74
7. Linde T, Sandhagen B, Wikstrom B, Danielson BG. The required dose of erythropoietin during renal anaemia treatment is related to the degree of impairment in erythrocyte deformability. Nephrol Dial Transplant 1997;12:2375-9
8. Roth D, Smith RD, Schulman G, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994;24:777-84
9. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-8
10. Sunder-Plassmann G, Patruta SI, Horl WH. Pathobiology of the role of iron in infection. Am J Kidney Dis 1999;34(4 Suppl 2):S25-9
11. Adamson JW, Eschbach JW. Management of the anaemia of chronic renal failure with recombinant erythropoietin. Q J Med 1989;73:1093-101
12. Muirhead N, Hodsman AB. Occult infection and resistance of anaemia to rHuEpo therapy in renal failure. Nephrol Dial Transplant 1990;5:232-4
13. Caro JJ. Anemia of chronic renal failure. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams' Hematology, 5th edn. New York: McGraw-Hill, 1995:456-62
14. Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61
15. Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-54
16. Holland DC, Lam M. Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study. Nephrol Dial Transplant 2000;15:650-8
17. Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int Suppl 2002:35-8
18. Raftery MJ, Auinger M, Hertlova M. Safety and tolerability of a multidose formulation of epoetin beta in dialysis patients. Collaborative Study Group. Clin Nephrol 2000;54:240-5
19. Ritz E, Eisenhardt A. Early epoetin treatment in patients with renal insufficiency. Nephrol Dial Transplant 2000;15(Suppl 3):40-4
20. Janatpour K, Holland PV. Noninfectious serious hazards of transfusion. Curr Hematol Rep 2002;1:149-55
21. House AA, Pham B, Page DE. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities. Nephrol Dial Transplant 1998;13:1763-9
22. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84
23. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98
24. European Medicines Agency (EMEA). Public statement: epoetins and the risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular risk in patients with chronic kidney disease. Available at: http://wwwemeaeuropaeu [Last accessed 2 January 2008]
25. Food and Drug Administration (FDA). Information for healthcare professionals: erythropoiesis stimulating agents (ESA). Available at: http://wwwfdagov/drug/Infosheets/HCP/RHE2007HCPhtm [Last accessed 2 January 2008]
26. Portales J, Torralbo A, Martin P, et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997;29:541-8
27. Furuland H, Linde T, Ahlmen J, et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003;18:353-61
28. Ross SD, Fahrbach K, Frame D, et al. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther 2003;25:1786-805
29. McMahon LP, McKenna MJ, Sangkabutra T, et al. Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplant 1999;14:1182-7
30. Pickett JL, Theberge DC, Brown WS, et al. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999;33:1122-30
31. Wu SC, Lin SL, Jeng FR. Influence of erythropoietin treatment on gonadotropic hormone levels and sexual function in male uremic patients. Scand J Urol Nephrol 2001;35:136-40
32. World Health Organization (WHO). WHO Informal Consultation on International Nonproprietary Names (INN) Policy for Biosimilar Products. Geneva, Switzerland: WHO, 2006. Available at: http://www.who.int/medicines/services/ inn/BiosimilarsINN_ReportSept2006.pdf [Last accessed 30 November 2007]
33. European Medicines Agency (EMEA). Questions and answers on biosimilar medicines (similar biological medicinal products). London: EMEA, 2007. Available at: http://www.emea.europa.eu/pdfs/human/pcwp/7456206en.pdf [Last accessed 30 November 2007]
34. European Generic Medicines Agency. Frequently asked questions about biosimilar medicines. Available at: http://www.egagenerics.com/FAQ-biosimilars. htm [Last accessed 2 January 2008]
35. European Association for Bioindustries (EuropaBio). Biological and biosimilar medicines. Brussels: EuropaBio, 2005. Available at: http://www.europabio.be/documents/FS-Biosimilar.pdf [Last accessed 30 November 2007]
36. European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products. CHMP/437/04. EMEA 2005. Available at: http://www.emea.europa.eu/pdfs/human/biosimilar/043704en. pdf [Last accessed 30 November 2007]
37. European Directorate for the Quality of Medicines & Healthcare (EDQM). The European Pharmacopoeia, 6th edn. Strasbourg: EDQM, 2007
38. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1-47
39. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75
40. Casadevall N, Dupuy E, Molho-Sabatier P, et al. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996;334:630-3
41. Casadevall N. Antibodies against rHuEPO: native and recombinant. Nephrol Dial Transplant 2002;17(Suppl 5):42-7
42. Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005;67:2346-53
43. Schellekens H. Lesson learned from Eprex-associated pure red cell aplasia. Kidney Blood Press Res 2007;30(Suppl 1):9-12
44. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992-1000
45. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60:741-7
46. Nissenson AR, Korbet S, Faber M, et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 1995;5:1517-29